187 related articles for article (PubMed ID: 27163538)
1. Targeting JAK/STAT Signaling to Prevent Rejection After Kidney Transplantation: A Reappraisal.
Baan CC; Kannegieter NM; Felipe CR; Tedesco Silva H
Transplantation; 2016 Sep; 100(9):1833-9. PubMed ID: 27163538
[TBL] [Abstract][Full Text] [Related]
2. Targeting JAK3 in kidney transplantation: current status and future options.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2011 Dec; 16(6):614-9. PubMed ID: 21971513
[TBL] [Abstract][Full Text] [Related]
3. Mammalian Target of Rapamycin Inhibitors and Nephrotoxicity: Fact or Fiction.
Barbari A; Maawad M; Kfoury Kassouf H; Kamel G
Exp Clin Transplant; 2015 Oct; 13(5):377-86. PubMed ID: 26450460
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib in kidney transplantation.
Wojciechowski D; Vincenti F
Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
[TBL] [Abstract][Full Text] [Related]
5. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.
Vafadari R; Weimar W; Baan CC
Clin Chim Acta; 2012 Sep; 413(17-18):1398-405. PubMed ID: 22261016
[TBL] [Abstract][Full Text] [Related]
6. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545.
Deuse T; Hua X; Taylor V; Stubbendorff M; Baluom M; Chen Y; Park G; Velden J; Streichert T; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2012 Oct; 94(7):695-702. PubMed ID: 22971540
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection.
Rovira J; Ramírez-Bajo MJ; Banon-Maneus E; Lazo-Rodríguez M; Moya-Rull D; Hierro-Garcia N; Tubita V; Piñeiro GJ; Revuelta I; Ventura-Aguiar P; Cucchiari D; Oppenheimer F; Brunet M; Campistol JM; Diekmann F
Transplantation; 2018 Jul; 102(7):1075-1084. PubMed ID: 29620612
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
10. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Webber AB; Vincenti F
Transplantation; 2016 Apr; 100(4):836-43. PubMed ID: 27003097
[TBL] [Abstract][Full Text] [Related]
11. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
12. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
Moore CA; Iasella CJ; Venkataramanan R; Lakkis FG; Smith RB; McDyer JF; Zeevi A; Ensor CR
Hum Immunol; 2017 Feb; 78(2):64-71. PubMed ID: 27998802
[TBL] [Abstract][Full Text] [Related]
14. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
Sommerer C; Giese T; Meuer S; Zeier M
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1030-7. PubMed ID: 21060169
[TBL] [Abstract][Full Text] [Related]
15. Treating inflammation with the Janus kinase inhibitor CP-690,550.
Vijayakrishnan L; Venkataramanan R; Gulati P
Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
[TBL] [Abstract][Full Text] [Related]
17. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
[TBL] [Abstract][Full Text] [Related]
18. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
19. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.
Deuse T; Velotta JB; Hoyt G; Govaert JA; Taylor V; Masuda E; Herlaar E; Park G; Carroll D; Pelletier MP; Robbins RC; Schrepfer S
Transplantation; 2008 Mar; 85(6):885-92. PubMed ID: 18360272
[TBL] [Abstract][Full Text] [Related]
20. Rationale for using belatacept in combination with sirolimus.
Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]